Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,402.82 -22.03 -0.13%
S&P 500 1,861.79 -0.52 -0.03%
NASDAQ 4,086.75 0.53 0.01%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,417.53 -0.15 -0.00%
TOPIX 1,166.59 0.04 0.00%
HANG SENG 22,760.24 64.23 0.28%

Abraham, Fruchter & Twersky, LLP Announces That a Class Action Lawsuit Has Been Filed against AVEO Pharmaceuticals, Inc.



  Abraham, Fruchter & Twersky, LLP Announces That a Class Action Lawsuit Has
  Been Filed against AVEO Pharmaceuticals, Inc.

Business Wire

NEW YORK -- May 14, 2013

Abraham, Fruchter & Twersky, LLP announces that a securities class action
lawsuit has been filed in the United States District Court for the District of
Massachusetts on behalf of all persons or entities who purchased the common
stock of AVEO Pharmaceuticals, Inc. (“AVEO” or the “Company”)(NASDAQ:AVEO)
between January 3, 2012 through May 1, 2013, inclusive (the “Class Period”).
The complaint alleges violations of Section 10(b) of the Securities and
Exchange Act of 1934 and Rule 10b-5, promulgated thereunder, against the
Company and certain of its officers and directors.

The complaint alleges that throughout the Class Period, defendants failed to
disclose that the U.S. Food and Drug Administration ("FDA") had recommended
that the Company conduct an additional phase 3 trial due to adverse trends in
the Company's first Phase III trial (TIVO-1) for Tivopath or Tivozanib, the
Company's product for the treatment of advanced kidney cancer. The complaint
also alleges that the Company had known but failed to disclose that there was
a 25% higher rate of death associated with Tivozanib compared to the control
drug, Sorafenib. In addition, the complaint alleges that the Company did not
disclose that almost 90% of the patients studied in the Company's Phase III
trial were enrolled from sites in Central and Eastern Europe where treatment
patterns were inconsistent with those in the United States. This information
that the Company knew and hid from the public was uncovered in the FDA’s April
30, 2013 Oncologic Drugs Advisory Committee (“ODAC”) Briefing Document.

On May 2, 2013, the ODAC voted by an overwhelming majority (13 to 1) not to
recommend approval of Tivozanib, because "the application...did not
demonstrate a favorable benefit-to-risk evaluation for the treatment of
advanced renal cell carcinoma (RCC) in an adequate and well-controlled trial."
On this news, AVEO shares declined another $2.61 per share or nearly 50%, to
close at $2.65 per share on May 2, 2013, on volume of over 15 million shares.

If you purchased the common stock of AVEO between January 3, 2012 through May
1, 2013 and would like to serve as lead plaintiff in this action, you must
move the Court no later than July 8, 2013. Any member of the proposed class
may move the Court to serve as lead plaintiff through counsel of their choice,
or may choose to do nothing and remain a member of the proposed class.

If you would like to discuss this action or if you have any questions
concerning this notice or your rights as a potential class member or lead
plaintiff, you may contact: Jack Fruchter or Arthur J. Chen of Abraham,
Fruchter & Twersky, LLP toll free at (800) 440-8986, or via e-mail at
info@aftlaw.com or achen@aftlaw.com.

Abraham, Fruchter & Twersky, LLP has extensive experience in securities class
action cases, and the firm has been ranked among the leading class action law
firms in terms of recoveries achieved by a survey of class action law firms
conducted by Institutional Shareholder Services.

Attorney Advertising. Prior Results Do Not Guarantee A Similar Outcome.

Contact:

Abraham, Fruchter & Twersky, LLP
Jack G. Fruchter / Arthur J. Chen, 800-440-8986
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement